Skip to main content

Table 1 Comparison of LDLT patients and surgery characteristics according to allocation group

From: Association between hospital acquired disability and post-discharge mortality in patients after living donor liver transplantation

 

Overall (n = 135)

HAD group (n = 47)

Non-HAD group (n = 88)

p-value

Gender, male, n (%)

73 (54.1)

25 (53.2)

48 (54.6)

1.000

Age, year

57.0 (52.0–62.0)

57.0 (51.0–65.0)

57.0 (52.0–62.0)

0.701

BMI, kg/m2

19.6 (17.0–22.3)

20.0 (17.0–22.1)

19.5 (16.9–22.5)

0.908

GNRI, points

81.6 (73.7–90.9)

81.6 (73.7–90.3)

81.8 (72.8–91.1)

0.702

 < 92

105 (77.8)

38 (80.9)

67 (76.1)

0.665

 ≥ 92

30 (22.2)

9 (19.2)

21 (23.9)

 

Type of disease, n (%)

 Primary biliary cirrhosis

11 (8.1)

6 (12.8)

5 (5.7)

0.557

 Primary sclerosing cholangitis

7 (5.2)

3 (6.4)

4 (4.6)

 

 Hepatitis B virus

15 (11.1)

4 (8.5)

11 (12.5)

 

 Hepatitis C virus

51 (37.8)

19 (40.4)

32 (36.4)

 

 Non-B, non-C liver cirrhosis

13 (9.6)

5 (10.6)

8 (9.1)

 

 Other

38 (28.1)

10 (21.3)

28 (31.8)

 

Comorbidity, n (%)

 Hepatocellular carcinoma

54 (40.0)

20 (42.6)

34 (38.6)

0.714

 Chronic kidney disease

59 (43.7)

23 (48.9)

36 (40.9)

0.467

Pre-operative eGFR, mL/min/1.73m2

66.9 (46.4–86.4)

62.0 (43.3–87.7)

69.8 (49.1–85.6)

0.722

Post-operative eGFR, mL/min/1.73m2

62.8 (46.1–74.4)

61.5 (46.2–74.1)

63.5 (45.9–74.4)

0.541

Δ eGFR (admission to discharge), mL/min/1.73m2

9.4 (− 10.3 to 20.8)

9.8 (− 10.3 to 30.3)

8.8 (− 10.7 to 18.0)

0.567

MELD score

16.0 (12.0–22.0)

15.0 (12.0–20.0)

17.0 (12.0–22.0)

0.393

Operation time, min

761.0 (701.0–849.0)

798.0 (710.0–925.0)

750.0 (695.0–820.3)

0.036

Operative blood loss, g

5550 (3550–9500)

7000 (3140–12,670)

4935 (3663–8735)

0.223

Donor age, year

33 (27–43)

33 (26.0–42.0)

33 (27.0–45.3)

0.914

Left lobe graft, n (%)

87 (64.4)

31 (66.0)

56 (63.6)

0.470

GW/SLV, %

40.2 (33.7–49.3)

39.7 (33.7–44.5)

41.4 (33.3–51.8)

0.170

ABO-incompatible, n (%)

30 (22.2)

8 (17.0)

22 (25.0)

0.076

SMI, cm2/m2

 Male, n (%)

44.5 (39.0–48.8)

44.5 (40.8–48.6)

44.4 (37.9–49.1)

0.803

 Female, n (%)

41.0 (36.1–47.9)

41. (37.9–49.2)

41.1 (34.9–47.7)

0.354

Initial walking, day

9 (6–15)

13.0 (7.0–19.0)

8.0 (6.0–12.8)

0.013

ICU length of stay, days

5 (4–8)

5.0 (4.0–9.0)

5.0 (4.0–7.8)

0.218

BI at admission, points

100 (90–100)

100 (100–100)

100 (80–100)

0.032

BI at hospital discharge, points

100 (90–100)

90 (70–95)

100 (100–100)

 < 0.001

Hospital length of stay, days

48.0 (37.0–67.0)

58.0 (46.0–76.0)

45.0 (36.0–58.8)

 < 0.001

Transfer to hospital, n (%)

29 (21.6)

18 (39.1)

11 (12.5)

0.001

Period after discharged from a hospital, months

28.1 (27.6–28.4)

27.8 (27.3–28.1)

28.2 (27.8–28.4)

 < 0.001

Cause of death, n (%)

13 (9.6)

10 (21.3)

3 (3.4)

0.189

 Factors of graft side

4 (3.0)

4 (8.5)

0

 

 Factors of recipient side

3 (2.2)

2 (4.3)

1 (1.1)

 

 Hepatocellular carcinoma recurrence

1 (0.7)

0

1 (1.1)

 

 Other carcinoma

3 (2.2)

3 (6.4)

0

 

 Other

2 (1.5)

1 (2.1)

1 (1.1)

 
  1. Values were reported as the median and Interquartile range (IQR) or number of subjects and percentage
  2. BI Barthel index; BMI body mass index; eGFR estimated glomerular filtration rate; GNRI Geriatric Nutritional Risk Index; GW/SLV: graft weight/standard liver volume; HAD hospital acquired disability; ICU intensive care unit; IQR interquartile range; LDLT living donor liver transplantation; MELD score model for end-stage liver disease score; SMI skeletal muscle index